1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Characteristics of patients, tumor histology, and MR imaging scanners in internal and external patient cohorts
Internal CohortExternal Cohort
Total patients29346
Median age at imaging (range) (yr)7.84 (0.24–21.71)9.42 (0.55–20.73)
Sex
 Male157 (53.5%)22 (47.8%)
 Female134 (45.7%)24 (52.1%)
 NA2 (0.6%)
Histology
 Low-grade glioma/astrocytoma152 (51.9%)21 (45.7%)
 High-grade glioma/astrocytoma23 (7.8%)3 (6.5%)
 Ependymoma7 (2.4%)0 (0%)
 Medulloblastoma85 (29%)17 (36.9%)
 Brainstem glioma15 (5.1%)2 (4.3%)
 Germinoma2 (0.7%)0 (0%)
 Other9 (3.1%)3 (6.5%)
Percentage of tumors containing each subregion
 ET85.0%91.3%
 NET95.0%93.5%
 CC68.3%84.8%
 ED43.3%58.7%
  • Note:—NA indicates not available.